18 and older, any sex, with Scars. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Patient and Observer Scar Assessment Scale (POSAS) - PI AssessmentPrimary· Post-excision at Month 3
POSAS is an established scale for assessing scar by both the patient and the observer. The overall opinion of the scar is reported on a scale of 1-10, with 1 being normal skin and 10 being the worst scar. Comparisons between treatment groups for efficacy analyses are based on 95% confidence intervals (CI) calculated using mixed models with treatment group as a fixed effect and subject as a random effect to account for multiple observations (i.e., scars) within subject.
Group
Value
95% CI
SLI-F06
4.4
± 1.7
Formulation Buffer
4.5
± 1.7
Patient and Observer Scar Assessment Scale (POSAS) - PI AssessmentPrimary· Post-abdominoplasty at Month 12
POSAS is an established scale for assessing scar by both the patient and the observer. The overall opinion of the scar is reported on a scale of 1-10, with 1 being normal skin and 10 being the worst scar. Comparisons between treatment groups for efficacy analyses are based on 95% confidence intervals (CI) calculated using mixed models with treatment group as a fixed effect and subject as a random effect to account for multiple observations (i.e., scars) within subject.
Group
Value
95% CI
SLI-F06
1.6
± 1.7
Formulation Buffer
1.7
± 1.7
Adverse events — posted to ClinicalTrials.gov
Time frame: Subjects were assessed at Visit 4a (Day 29), Visit 5a (Day 57 - Group 2 only), Visit 6a (Day 85 - Group 1 only), Visits 3b-12b (M1-3, 6, 9, 12, 15, 18, 21 and 24 at study exit)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
SLI-F06
Serious: 3/22 (14%)
Deaths: 0/22
Formulation Buffer
Serious: 3/22 (14%)
Deaths: 0/22
Serious adverse events (3 terms)
Reaction
System
SLI-F06
Formulation Buffer
Pulmonary embolism
Vascular disorders
—
—
Abortion spontaneous
Pregnancy, puerperium and perinatal conditions
—
—
Nephrolithiasis
Renal and urinary disorders
—
—
Other adverse events (37 terms — click to expand)
Reaction
System
SLI-F06
Formulation Buffer
Cellulitis
Infections and infestations
—
—
Nasopharyngitis
Infections and infestations
—
—
Seroma drainage
Surgical and medical procedures
—
—
Umbilical hernia
Gastrointestinal disorders
—
—
Alopecia
Skin and subcutaneous tissue disorders
—
—
Skin necrosis
Skin and subcutaneous tissue disorders
—
—
Seroma
Injury, poisoning and procedural complications
—
—
Pyrexia
General disorders
—
—
Headache
Nervous system disorders
—
—
Aortic arteriosclerosis
Vascular disorders
—
—
Abdominal hernia
Gastrointestinal disorders
—
—
Pneumonia
Respiratory, thoracic and mediastinal disorders
—
—
Dermoid cyst
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
—
Ascites
Gastrointestinal disorders
—
—
Atelectasis
Respiratory, thoracic and mediastinal disorders
—
—
Synovial cyst
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multicenter, double-blind study comparing SLI-F06 to vehicle formulation buffer for the improvement in scar appearance and wound strength in routine surgical excisions, as well as post-operative abdominoplasty scar appearance.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scarless Laboratories, Inc.
Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880058.